Finally, our findings of increased brain cytokines and plasma TNFR1 and TNFR2 support hypotheses that targeting post-stroke inflammation is a promising add-on therapy in ischemic stroke patients. This evidence concerns the gene TNFRSF1B and ischemic stroke.